Home » Newsletters » BioWorld Science

BioWorld Science

July 23, 2014

View Archived Issues

Development of a live-attenuated HIV-1 virus incapable of reactivation

Passive immunization against N-terminally truncated beta-amyloid species with NT4X-167 tested

Enrollment open in phase I study of SM-04755 in colorectal, gastric, hepatic or pancreatic cancer

Celladon in-licenses gene therapy application rights for mSCF for cardiac ischemia treatment

MetaMax initiates phase I/IIa study of MM-D37K

Shire recaps progress of second quarter 2014

Cerecor raises funds to support development of pipeline

Sorrento Therapeutics receives NCI grant for Myc inhibitor

NIBIB award supports Celsion's development of ThermoDox for brain tumors

Implantation of cells secreting NGF proves safe in Alzheimer's disease study

Cadila Healthcare discloses new PARP-1 inhibitors

Celon Pharma describes novel PDE9A inhibitors with procognitive potential

Shionogi patents novel cephems

Researchers present phase II data for ELND-005

Roche synthesizes novel COMT inhibitors

Scientists at OriBase Pharma divulge novel protein kinase inhibitors

FDA grants orphan drug status to palovarotene for FOP

European group designs new agents for viral infections

Ganetespib advances into phase III extension of AML LI-1 study

Pierre Fabre presents novel agents for schizophrenia and other disorders

Anavex Life Sciences secures cGMP manufacturing for ANAVEX 2-73

Sage Therapeutics receives fast track designation for SAGE-547

Kyorin signs license agreement with Merck & Co. for vibegron

First phase I trial of JZP-386 begins

Teva acquires Labrys and enhances migraine portfolio

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...